Sense Biodetection has obtained CE Mark for its new molecular diagnostic test, Veros Covid-19.

The new test provides accurate, instrument-free, laboratory-quality results in 15 minutes using patient-friendly anterior nasal swabs.

It is fully portable, disposable, self-contained and easy to use, without any need for an external power supply or additional reader.

Claimed to be the first and only fully integrated molecular diagnostic test, Veros Covid-19 has been designed to be used in near-patient environments, such as pharmacies, care homes, hospital emergency departments and urgent care centres.

The company stated that the test demonstrated 95.2% sensitivity, 97.9% accuracy and 99.5% specificity in a multicentre trial that enrolled approximately 300 subjects during the Delta and Omicron surges.

Results obtained from the Veros Covid-19 test were compared to a CE Marked and WHO and US Food and Drug Administration Emergency Use Authorized qRT-PCR assay.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects to initially launch the test in Ireland, as well as the Benelux and Nordic regions of Europe.

Sense Biodetection CEO Timothy Still said: “Obtaining our first regulatory approval is a pivotal milestone for Sense, allowing us to deliver on our founders’ vision in 2014 to empower patients and clinicians with a pioneering new class of diagnostic product.

“This is the first step in our ambitious plan to develop a wide range of tests on the Veros platform to transform the treatment of many other infectious diseases, including influenza, respiratory syncytial virus (RSV) and sexually transmitted pathogens.”

Last month, Sense Biodetection signed a distribution agreement with Una Health for the Veros Covid-19 Test in the UK.